Letter to the editor referring to the publication entitled "The role of antagonists of the PD-1: PD-L1/PD-L2 axis in head and neck cancer treatment" by Pai et al

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F16%3A00066737" target="_blank" >RIV/65269705:_____/16:00066737 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/16:00092818
Result on the web
<a href="http://www.oraloncology.com/article/S1368-8375(16)30135-X/abstract" target="_blank" >http://www.oraloncology.com/article/S1368-8375(16)30135-X/abstract</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.oraloncology.2016.08.007" target="_blank" >10.1016/j.oraloncology.2016.08.007</a>

Result language
angličtina
Original language name
Letter to the editor referring to the publication entitled "The role of antagonists of the PD-1: PD-L1/PD-L2 axis in head and neck cancer treatment" by Pai et al
Original language description
As addressed by Pai with co-workers in their comprehensive review, novel immunotherapeutic strategies using immune checkpoint inhibitors represent a promising area of research in squamous cell carcinoma of the head and neck (SCCHN) [1]. Results from a phase III trial and preliminary data from three early clinical studies demonstrated the efficacy of monoclonal antibodies against programmed death-1 (PD-1) receptor (nivolumab, pembrolizumab) and its ligand PD-L1 (durvalumab) as second-line treatments in the recurrent and/or metastatic (R/M) setting. With relatively low incidence of serious adverse events, these agents elicited durable responses even in patients with refractory disease. Moreover, nivolumab, as the first drug ever, significantly improved overall survival (OS) by 2.4 months compared with investigator's choice (single-agent chemotherapy or cetuximab) [1-4]. From a broader perspective, these pioneering studies have important implications for future trial design with one of the challenges being the selection of appropriate clinical endpoints associated with benefits of immune checkpoint inhibitors.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—

Publication year
2016
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)